Moran Elishmereni

Moran has led a number of IMBM projects in the context of cancer therapy. The field of immunity was focally underscored in her work involving mathematical models describing dynamical interactions between the tumor and the immune system. In these complex systems, Moran has been examining the influence of different therapeutic agents and their optimized clinical application in cancer. Models featuring Interleukin (IL)-11, IL-12, IL-21 were designed using preclinical and clinical data from the literature and open-access databases, deriving important therapeutic insights concerning cytokine therapy. In a model developed with Yuri Kogan, Moran also studied the Th1/Th2 imbalance of the immune system in cancerous settings. She also joined the efforts to build a model for cellular vaccination therapy in advanced prostate cancer; this model was subsequently validated using retrospective clinical data, through a collaboration with Prof. Stanimir Vuk-Pavlovic (Mayo Clinic Rochester, USA). The team followed up by developing a novel and general approach for real-time model-aided personalization of vaccination therapy. Moran later designed dynamic models for progression of advanced prostate cancer, fit for the clinical realm by training and validation on patient data. A mathematical/statistical model-based algorithm was designed by Moran and colleagues, in collaboration with Dr. Manish Kohli at Mayo Clinic Rochester, USA, for predicting individual progression of hormone-sensitive prostate cancer patients to androgen deprivation therapy. Moran continues to develop model-based applications for various cancer indications and therapeutic settings.


    1. Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate, 2016 76(1) pp. 48-57.

    2. Kheifetz Y, Elishmereni M, Agur Z. Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein. J Pharmacokinet Pharmacodyn, 2014 41(5) pp.479-91.

    3. Ribba B, Holford NH, Magni P, Troconiz I, Gueorguieva I, Girard P, Sarr C, Elishmereni M, Kloft C, Friberg LE. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst Pharmacol., 2014 3:e113.

    4. Agur Z, Elishmereni M, Kheifetz Y. Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. Wiley Interdiscip Rev Syst Biol Med., 2014 6(3) pp.239-53.

    5. Elishmereni M, Fyhrquist N, Singh Gangwar R, Lehtimaki S, Alenius H, Levi-Schaffer F. Complex 2B4 regulation of mast cells and eosinophils in Murine Allergic Inflammation. J Invest Dermatol., 2014 134(12) pp.2928-37.

    6. Elishmereni M, Bachelet I, Ben-Efraim AH, Mankuta D, Levi-Schaffer F. Interacting mast cells and eosinophils acquire an enhanced activation state in vitro. Allergy, 2013 68(2):171-9.

    7. Kogan Y, Halevi-Tobias K, Elishmereni M, Vuk-Pavlovic S, Agur Z. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. Cancer Res., 2012 1;72(9) pp.2218-27.

    8. Elishmereni M, Kheifetz Y, Sondergaard H, Overgaard RV, Agur Z. An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers. PLoS Comput Biol., 2011 7(9):e1002206.

    9. Kronik N, Kogan Y, Elishmereni M, Halevi-Tobias K, Vuk-Pavlovic S, Agur Z. Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS One. 2010 5(12):e15482.

    10. Elishmereni M, Alenius HT, Bradding P, Mizrahi S, Shikotra A, Minai-Fleminger Y, Mankuta D, Eliashar R, Zabucchi G, Levi-Schaffer F. Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro. Allergy. 2011 66(3) pp.376-85.

    11. Elishmereni M, Levi-Schaffer F. CD48: A co-stimulatory receptor of immunity. Int J Biochem Cell Biol. 2011 43(1) pp.25-8.

    12. Minai-Fleminger Y, Elishmereni M, Vita F, Soranzo MR, Mankuta D, Zabucchi G, Levi-Schaffer F. Ultrastructural evidence for human mast cell-eosinophil interactions in vitro. Cell Tissue Res. 2010;341(3):405-15. (Equal contribution with 1st author).

    13. Elishmereni M, Levi-Schaffer F. Skin disorders of inflammation and immune suppression in young and elder: A special role for mast cells. Handbook of skin aging: Market prospective, pharmacology, formulation and evaluation, Dayan Nava Ed., William Andrew Publishing, New York.

    14. Elishmereni M, Bachelet I, Levi-Schaffer F. DNAM-1: An amplifier of immune responses as a therapeutic target in various disorders. Current Opinion in Investigational Drugs 2008 9(5) pp.491-6.

    15. Cappuccio A, Elishmereni M, Agur Z. Optimization of Interleukin-21 immunotherapeutic strategies. Journal of Theoretical Biology, 2007 248(2) pp.259-66.

    16. Kheifetz Y, Elishmereni M, Horowitz S, Agur Z. (2006). Fluid-retention side-effects of the chemotherapy-supportive treatment Interleukin-11: Mathematical modelling of putative underlying mechanisms. Computational and Mathematical Methods in Medicine, 7(2-3):71-84.

    17. Cappuccio A, Elishmereni M, Agur Z. (2006). Cancer immunotherapy by Interleukin-21: Potential treatment strategies evaluated in a mathematical model. Cancer Research, 66(14):7293-300.